Scientists at the McGovern Institute for Brain Research at MIT and the Broad Institute of MIT and Harvard have re-engineered ...

Scientists at the McGovern Institute and the Broad Institute of MIT and Harvard have reengineered a compact RNA-guided enzyme ...

N of 1 therapy uniquely developed for infant with life-threatening rare metabolic disorder in six months by Aldevron and ...

Somatic hypermutation (SHM) of immunoglobulin variable (V) regions modulates antibody-antigen affinity is initiated by activation-induced cytidine deaminase (AID) on single-stranded DNA (ssDNA).

Regents of the Univ. of California v. Broad Inst., Inc., No. 2022-1594, 2025 WL 1363125 (Fed. Cir. May 12, 2025) - On May 12, ...

Treated with an individualized gene-editing therapy that corrects mutations directly on the genome, a patient shows ...

G ene therapy has always held enormous promise to correct genetic diseases, but turning that potential into treatments has ...

Current setbacks cannot prevent gene-editing companies from advancing closer to “one-and-done” cures and new products.

Researchers have engineered a compact, high-specificity IscB variant, NovaIscB, for safe, persistent in vivo epigenome ...

A study published in The New England Journal of Medicine looks at a new CRISPR gene therapy for children with a rare genetic disease. Dr Alena Pance, Senior Lecturer in Genetics, University of ...